To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
To read the full story
Related Article
- Sumitomo Dainippon’s April-December Sales Up 2.9% as Diabetes Meds Counter Off-Patent Dip
January 31, 2020
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
September 9, 2019
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Shionogi’s Delgocitinib Wins Nod in China through LEO Pharma
November 18, 2026
- RaQualia’s Reflux Therapy Scores Approval in Brazil
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





